| My Account | Subscribe | Contact Us | Donate |
Home
- The Edmonton Protocol and Me
- Olympia Dukakis and Her Husband Tackle Type 2
- Surfing with Type 1
- Behind the Wheel, But Still in Control
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Medications Research Articles
Unlike most vaccines, which work by “teaching” the immune system to attack something, this one would instruct it to avoid attacking pancreatic beta cells—the haywire autoimmune response responsible for the onset of type 1.
Vaccine to Suppress Type 1 Onset in At-Risk Children Could Be Based on Enzyme
Georgia researchers believe that a powerful enzyme that inhibits or modifies immune system response could be the basis for a vaccine administered to children at high risk for developing type 1 diabetes.
Unlike most vaccines, which work by "teaching" the immune system to attack something, this one would instruct it to avoid attacking pancreatic beta cells-the haywire autoimmune response responsible for the onset of type 1.
The enzyme, called indoleomine 2,3-dioxegenase (IDO), is an immune system inhibitor that fetuses use to fend off or prevent an immune response directed against them by their mothers' bodies.
In their experiments with IDO, scientists at the Medical College of Georgia Immunotherapy Center in Augusta bundled the enzyme with dendritic cells, which are the cells that "tell" the body's powerful T cells to launch an attack. Apparently the dendritic cells' association with IDO was enough to keep the body's powerful immune system warriors pacified.
Children at risk of developing type 1 do not have any or enough IDO associated with their dendritic cells, which leads them to invite T cell attacks on pancreatic beta cells. A vaccine that could increase dendritic cells' association with IDO would prevent, perhaps permanently, the T cell attack that eventually destroys the insulin-producing capability in patients' pancreases and signals the onset of type 1.
Categories: Kids & Teens, Medications, Medications Research, Type 1 Issues
Facebook
MySpace 
Digg
You May Also Be Interested In...
Click Here To View Or Post Comments
0 comments -
Feb 25, 2009 -
Email to a Friend
Send a link to this page to your friends and colleagues.